NASDAQ
30.10.26 | 20:59
15,040 US-Dollar
+0,07 % +0,010
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA | 1 | GlobeNewswire (USA) | ||
| 08.10. | Cullinan Therapeutics: Erster Patient in zulassungsrelevanter AML-Studie behandelt | 9 | Investing.com Deutsch | ||
| 02.10. | H.C. Wainwright bestätigt Cullinan Oncology nach NDA-Antrag mit "Kaufen" | 2 | Investing.com Deutsch | ||
| 02.10. | Cullinan Therapeutics, Inc.: New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program | 284 | GlobeNewswire (Europe) | In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the... ► Artikel lesen | |
| 24.09. | Cullinan Therapeutics auf Stifel-Forum: Fortschritte und Risiken in der Autoimmun-Pipeline | 1 | Investing.com Deutsch | ||
| 24.09. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.09. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio | 288 | GlobeNewswire (Europe) | Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren's disease in December CLN-049 (FLT3 TCE)... ► Artikel lesen | |
| 21.09. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum | 4 | GlobeNewswire (USA) | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.09. | BTIG hebt Kursziel für Cullinan Oncology nach Studiendaten an | 12 | Investing.com Deutsch | ||
| 14.09. | BTIG raises Cullinan Oncology stock price target on trial data | 2 | Investing.com | ||
| 14.09. | Stifel bekräftigt Kaufempfehlung für Cullinan Oncology Aktie nach Studiendaten | 3 | Investing.com Deutsch | ||
| 14.09. | Cullinan Oncology Aktie: TD Cowen bekräftigt Kaufempfehlung | 2 | Investing.com Deutsch | ||
| 14.09. | Stifel reiterates Cullinan Oncology stock Buy rating on trial data | 1 | Investing.com | ||
| 14.09. | Cullinan Oncology stock rating reaffirmed at Buy by TD Cowen | 2 | Investing.com | ||
| 14.09. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.08. | UBS raises Cullinan Oncology stock price target to $27 on trial data | 4 | Investing.com | ||
| 12.08. | Biotech Stocks At 52-Week Highs - Alamar Biosciences +30% on Q2 Reports, Dyne Therapeutics, Cullinan Therapeutics, DexCom, Cardinal Health | 2.807 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports.Alamar Biosciences Inc.... ► Artikel lesen | |
| 06.08. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results | 1.026 | GlobeNewswire (Europe) | CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (BCMA TCE) multi-dose regimen data in SLE in Q4 2026; Phase... ► Artikel lesen | |
| 06.08. | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 06.08. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 4,451 | -1,13 % | Clinuvel Pharmaceuticals Ltd - 20-F, Annual and transition report of foreign private issuers | ||
| BIOCRYST PHARMACEUTICALS | 7,590 | +0,37 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth | -Supports BioCryst's evolution toward a more disciplined R&D model centered on external innovation- RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,062 | +5,57 % | BioNTech sucht den Durchbruch mit der Krebs-Pipeline, DroneShield kämpft gegen Shortseller und Cardiol Therapeutics visiert den Rebound an! | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Biotech-Größen wie z. B. BioNTech und Rüstungs- und Drohnenwerte wie DroneShield suchen aktuell nach eindeutigen und klaren Trendsignalen.... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,840 | +1,59 % | Arbutus Biopharma Corporation: Arbutus Announces Final Results of Its US$230 Million Modified "Dutch Auction" Tender Offer | WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,795 | 0,00 % | Cardiff Oncology ernennt Dr. Leila Alland zur Interims-Chief-Medical-Officer | ||
| ALDEYRA | 0,498 | 0,00 % | H.C. Wainwright bestätigt Aldeyra-Aktie mit "Neutral" und Kursziel von 2 US-Dollar | ||
| DENALI THERAPEUTICS | 16,965 | -0,41 % | Denali Therapeutics Inc.: Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH (tividenofusp alfa-eknm) as Best Biotechnology Product | ||
| ABCELLERA BIOLOGICS | 10,960 | -0,36 % | Jefferies nimmt AbCellera mit "Buy" auf - Kursziel 21,00 $ | ||
| ADAPTIVE BIOTECHNOLOGIES | 24,950 | +4,66 % | Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure | SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune... ► Artikel lesen | |
| AC IMMUNE | 2,070 | +4,44 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| COHERUS ONCOLOGY | 0,735 | -1,87 % | Coherus Oncology, Inc. - 8-K, Current Report | ||
| HELUS PHARMA | 9,550 | +1,38 % | Helus Pharma Inc: Helus Pharma appoints Lawson as chair | ||
| CYTOMX THERAPEUTICS | 2,072 | -0,48 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen | |
| AGENUS | 6,450 | +4,88 % | Agenus Inc.: Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026 | The cohort met its primary endpoint of major pathologic response, with 83% of patients having little or no cancer remaining at surgery in a high-risk, locally advanced population Side effects... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 11,000 | -0,27 % | Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call |
CULLINAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 15,040 Euro und damit +0,07 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.